FierceBiotech’s recent feature about 2014’s Most Successful Biotech IPOs include Bay-Area based Ultragenyx and Avalanche.
From the story:
“Scoop: Among 2014’s early high fliers, only Ultragenyx was able to sustain its Wall Street performance throughout the year, avoiding the fate of fellow winter boom beneficiaries Dicerna and uniQure. The 2013 Fierce 15 honoree moved 5.8 million shares and above its expected range, and its share price has soared ever since.”
“Scoop: Taking advantage of industry-wide renewed optimism for gene therapies, Avalanche was able to bank $102 million in an upsized offering that priced at the top of an upwardly revised range. That haul came just months after the biotech closed a $55 million venture round, and investor confidence in its stable of potential one-time treatments for ocular diseases has helped more than double the company’s share price since July.”